Department of Head and Neck Oncology and Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Biometrics Department, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Head Neck. 2019 Mar;41(3):623-631. doi: 10.1002/hed.25364. Epub 2019 Jan 7.
With the increasing necessity for total laryngectomy (TL) after prior (chemo)radiotherapy, prosthetic vocal rehabilitation outcomes might have changed.
Retrospective cohort study including all patients laryngectomized between 2000 and 2012 with a voice prosthesis (VP) in the Netherlands Cancer Institute.
Median device lifetimes of the standard Provox2 and Vega VPs are 63 and 66 days, respectively, and for the problem-solving ActiValve Light and Strong VPs 143 and 186 days, respectively. In multivariable analysis, salvage TL and TL for a dysfunctional larynx (compared to primary TL) were associated with a shorter device lifetime. Almost half of the patients (48%) experienced tracheoesophageal puncture tract-related problems, and this concerned 12% of all VP replacements.
Compared to historical cohorts, device lifetimes of regular Provox2 and Vega voice prostheses have decreased. Complications are not occurring more frequently but affect more patients. Nevertheless, the clinical reliability and validity of prosthetic voice rehabilitation is still sound.
由于先前(放化疗)后全喉切除术(TL)的必要性增加,假体发声康复的效果可能已经发生了变化。
回顾性队列研究包括 2000 年至 2012 年间在荷兰癌症研究所使用声门假体(VP)的所有患者。
标准 Provox2 和 Vega VP 的中位装置寿命分别为 63 天和 66 天,而问题解决型 ActiValve Light 和 Strong VP 的寿命分别为 143 天和 186 天。多变量分析表明,挽救性 TL 和因功能失调的喉而进行的 TL(与原发性 TL 相比)与装置寿命较短相关。近一半的患者(48%)经历了气管食管穿刺道相关问题,这占所有 VP 更换的 12%。
与历史队列相比,常规 Provox2 和 Vega 语音假体的使用寿命已经缩短。并发症并没有更频繁地发生,而是影响了更多的患者。然而,假体发声康复的临床可靠性和有效性仍然存在。